You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 84 No. 6, December 1961 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (9)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Chelation Therapy in Cutaneous Porphyria

A Review and Report of a Five-Year Recovery

SHERWYN M. WOODS, M.D.; HENRY A. PETERS, M.D.; STURE A. M. JOHNSON, M.D.

Arch Dermatol. 1961;84(6):920-927.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Porphyria cutanea tarda is a disease of porphyrin metabolism associated with vesiculobullous eruptions on the sunlight-exposed surfaces of the skin after solar radiation, heat, or trauma, and often associated with pigmentation, shallow scarring, and hypertrichosis. Treatment in the past has primarily been aimed at avoidance of precipitants such as sunlight, hepatotoxic agents, and alcohol. Successful long-term recovery has not previously been reported.

Encouraging results with chelation therapy have been noted in the treatment of acute porphyria with abdomino-neurological-psychiatric symptomatology by Peters1-5 and others.6-9 The authors in 1958 reported on the first case of cutaneous porphyria successfully treated by calcium disodium edathamil (Calcium Disodium Versenate).10 This patient has now been studied longitudinally for a period of 8 years. The first 3 years, those prior to chelation therapy, were associated with severe and persistent manifestations of porphyria cutanea tarda. There has been a total absence of all symptomatology for . . . [Full Text PDF of this Article]


Author Affiliations

MADISON, WIS.

From the University Hospitals, University of Wisconsin, Madison, Wisconsin; Instructor in Psychiatry, University of Wisconsin Medical School (Dr. Woods); Associate Professor of Neuropsychiatry (Dr. Peters); Professor of Dermatology, University of Wisconsin Medical School (Dr. Johnson).


Footnotes

Submitted for publication July 20, 1961.

Laboratory research studies were aided by Grant No. 484-3482 from the National Institutes of Health.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1961 American Medical Association. All Rights Reserved.